The Pediatric Sleep Study

November 5, 2026 updated by: Olly, PBC

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of a Dietary Gummy on Sleep Outcomes in Children Aged 4-16 With Parent/Guardian-Reported Sleep Concerns

The goal of this clinical trial is to learn if a melatonin-free sleep gummy (a chewable dietary supplement) improves sleep in children aged 4 to 16 whose parents report sleep concerns. It will also learn about the safety and tolerability of the gummy. The main questions it aims to answer are:

  1. Does the gummy improve the child's sleep disturbance, compared with a look-alike gummy?
  2. Does the gummy change daytime problems linked to poor sleep, sleep habits, and the parent's overall impression of the child's sleep?
  3. What medical problems do children have when taking the gummy?

Researchers will compare the sleep gummy to a placebo (a look-alike gummy that contains no active ingredient) to see if the sleep gummy improves sleep.

Participants will:

  1. Complete about 1 week of baseline questionnaires and diaries, then take 2 gummies once a day in the evening for 4 weeks, with a parent or guardian supervising
  2. Take part from home, with no clinic visits, using the Chloe study app
  3. Answer sleep questionnaires every week, a sleep habits questionnaire every 2 weeks, and a safety survey every week
  4. Have a parent or guardian keep a daily diary of sleep, naps, mood, activity, and the time the gummies were taken
  5. Some participants (an optional group of 60) will also wear a wrist device (a fitness tracker/smartwatch) at night to measure sleep

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Each family takes part for up to about 11 weeks in total which includes a 1 week baseline period and a 4 week study product/placebo use period.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
200

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90045
        • People Science, Inc.
        • Principal Investigator:
          • Noah Craft, MD, PhD
        • Contact:
        • Sub-Investigator:
          • Marie C Erfe, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

4 years to 16 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Child is aged 4 to 16 years, inclusive, at screening.
  • Parent or legal guardian reports current concerns about the child's sleep (for example, difficulty falling asleep, staying asleep, or keeping a consistent sleep routine) and confirms the child has no diagnosed sleep disorder.
  • Parent or legal guardian can read and understand English.
  • Parent or legal guardian can read, understand, and give informed consent on behalf of the child; the child gives age-appropriate assent where applicable.
  • Parent or legal guardian can use a personal smartphone and download Chloe by People Science.
  • Parent or legal guardian can receive shipment of the study product or placebo, and any wearable device, at an address within the United States.
  • Parent or legal guardian can support the child in completing study assessments for up to 11 weeks.
  • Child is willing and able to consume the gummy and can safely chew and swallow gummy products.
  • Parent or legal guardian agrees to keep the child's current lifestyle, diet, bedtime routine, and physical activity for the whole study.
  • Child has a regular sleep-wake cycle with a consistent bedtime and wake time (within about 1 hour on weekdays and weekends) for at least 3 weeks before baseline, and agrees to keep this schedule during the study.

Exclusion Criteria:

  • No personal smartphone, no internet access, or unwilling to download Chloe.
  • Child has a diagnosed sleep disorder needing medical management (for example, obstructive sleep apnea, narcolepsy, or restless leg syndrome).
  • Child snores loudly on most nights, has been seen to stop breathing, gasp, or choke during sleep, or has been referred for a sleep evaluation that is not yet complete.
  • Use of melatonin, prescription sleep medication, or other sleep aids (including over-the-counter antihistamines used for sleep and CBD or hemp products) within 28 days before screening, or expected use during the study.
  • Regular caffeine intake of more than 1 caffeinated beverage (over 110 mg) per day, or unwillingness to keep caffeine intake stable and avoid caffeine after mid-afternoon.
  • Use of a standalone magnesium supplement, or any dietary supplement marketed for sleep, stress, relaxation, mood, or focus, within 30 days before randomization or during the study. A stable-dose standard children's multivitamin is allowed.
  • Any investigational therapy within 30 days before randomization.
  • Known allergy or hypersensitivity to any study product or placebo ingredient, to Asteraceae (daisy family) plants, or to soy, egg, peanut, tree nuts, shellfish, milk, wheat, or sesame.
  • Any medical, neurodevelopmental, or psychiatric condition that, in the Principal Investigator's opinion, may confound sleep outcomes or affect participation.
  • Significant illness, disease, or condition that, in the Principal Investigator's opinion, may affect participation or outcomes.
  • Unlikely to be able to comply with the study, or considered unsuited by the Principal Investigator.
  • History or presence of a clinically diagnosed neurologic, cardiac, renal, hepatic, endocrine (including diabetes), pulmonary, biliary, or gastrointestinal condition. Well-controlled asthma managed with as-needed medication, seasonal allergies, and mild eczema are not exclusions.
  • Body mass index at or above the 95th percentile for age and sex.
  • Use of angiotensin-converting enzyme inhibitors, other magnesium-retaining drugs, or potassium-sparing diuretics.
  • Other diseases or medications that might interfere with the study or put the participant's health at risk.
  • Immune insufficiency (such as selective IgA deficiency, common variable immunodeficiency, or X-linked agammaglobulinemia).
  • Taking any prescription medication or dietary supplement for anxiety, depression, mood, stress, focus, or attention-deficit/hyperactivity disorder.
  • Known liver dysfunction.
  • Use of systemic corticosteroids or immunosuppressant drugs.
  • History of cancer within the past 5 years.
  • Planned surgery or invasive medical procedures during the study.
  • Planned travel during baseline or the use period that involves a time zone change or 2 or more consecutive nights away from the usual sleep environment.
  • Parent or legal guardian cannot communicate with the study team or complete study procedures, or child has a condition that would prevent completing assent or assessments.
  • Child or household member of an employee of People Science or the Sponsor (Unilever/Olly).
  • Pregnant or breastfeeding (self-reported).
  • Another child in the same household is already enrolled.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Active Product

Under parent/guardian supervision, participant takes 2 gummies once per evening for 4 weeks.
Dietary supplement: Olly melatonin-free supplement

Melatonin-free supplement intended for children who experience mild-to-moderate sleep concerns. Contains magnesium, l-theanine, lemon balm extract, and chamomile.
Placebo Comparator: Placebo

Under parent/guardian supervision, participants 2 gummies oncer per evening for 4 weeks
Dietary supplement: Placebo Supplement

The placebo gummy matches the study product in appearance, flavor, texture, and packaging and contains no active ingredients.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Sleep Disturbance T-Score
Time Frame: Baseline and weekly through Week 4 of the product or placebo use period

Age-appropriate PROMIS Pediatric Sleep Disturbance measure covering the past 7 days, reported as a T-score. Higher scores mean more sleep disturbance.
Baseline and weekly through Week 4 of the product or placebo use period

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change from Baseline in PROMIS Pediatric Sleep-Related Impairment T-Score
Time Frame: Baseline and weekly through Week 4 of the product or placebo use period

Age-appropriate PROMIS measure of the daytime effects of poor sleep over the past 7 days, reported as a T-score. Higher scores mean more sleep-related impairment.
Baseline and weekly through Week 4 of the product or placebo use period
Change from Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score
Time Frame: Baseline and Weeks 2 and 4 of the product or placebo use period

Parent-completed 33-item questionnaire of children's sleep behavior. Higher total scores mean more sleep problems.
Baseline and Weeks 2 and 4 of the product or placebo use period
Parent/Guardian Global Impression of Change (PGIC-Proxy) Rating at Week 4
Time Frame: Week 4 of the product or placebo use period

Single parent- or guardian-rated item on a 7-point scale from 1 (very much improved) to 7 (very much worse), comparing the child's sleep with baseline.
Week 4 of the product or placebo use period
Change from Baseline in Wearable-Derived Sleep Metrics in the Wearable Substudy
Time Frame: Nightly during the baseline week and the 4-week product or placebo use period.

Objective sleep metrics collected nightly by a wrist-worn consumer wearable device in a subset of participants.
Nightly during the baseline week and the 4-week product or placebo use period.
Number of Participants with Adverse Events and Serious Adverse Events
Time Frame: From the start to end of the study product/placebo use period through (Days 8-35)

Adverse events and serious adverse events reported by parents or guardians and assessed by the investigator.
From the start to end of the study product/placebo use period through (Days 8-35)

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Parent or Guardian Sleep Daily Diary Responses
Time Frame: Daily from the baseline week through the end of the 4-week product or placebo use period.

Daily diary completed by the parent or guardian covering the child's sleep, naps, mood, activity, medication changes, and time of product administration.
Daily from the baseline week through the end of the 4-week product or placebo use period.
End-of-Study Experience Survey Responses
Time Frame: Once, after completion of the Week 4 assessment

Survey about the study design, product use, product experience, and use of the study app. Responses are used to identify improvements for future participant-centered study designs.
Once, after completion of the Week 4 assessment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Olly, PBC

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
People Science, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Noah Craft, MD, PhD, People Science, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 9, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 5, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • OLY-KDS-0008
  • PS60 (Other Identifier: People Science)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Only coded, de-identified data are delivered to the sponsor. Identifiable data are not shared with the sponsor or any third party. Any release of study data to third parties requires written approval of the Principal Investigator.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings